Loading data...
Psilocybin-Research.com Searchable psilocybin and psilocin bibliometrics.

Application overview

Source-labeled psilocybin and psilocin literature for search, monitoring, export, and citation workflows.

Research workflow

Search, filter, export, analyze, and monitor psilocybin and psilocin publications with source labels, publication status, citation links, alerts, API access, and full SQLite download.

Databases used

  • PubMed
  • Crossref
  • Europe PMC
  • OpenAlex
  • medRxiv
  • bioRxiv
  • PsyArXiv
  • ClinicalTrials.gov

Psilocybin and psilocin research index

Find psilocybin and psilocin papers, preprints, trials, and citations with clear source context.

Database 4,054 indexed records
Current display Latest publications Full SQLite index sorted by newest first. Use search or filters to narrow the list.
Database 4,054 indexed records
4,054 Total Publications 3,914 Psilocybin Records 569 Psilocin Records 569 Search Matches 826 Journals 66 Research Topics
Published 3,317 Peer-reviewed / formal records
Preprints 450 Marked as not peer reviewed
Clinical trials 287 ClinicalTrials.gov records
Source coverage 8 active sources
Source Count Share Status
Europe PMC 1,652 40.7% Active
OpenAlex 1,401 34.6% Active
ClinicalTrials.gov 287 7.1% Active
PubMed 278 6.9% Active
PsyArXiv 191 4.7% Active
bioRxiv 142 3.5% Active
Crossref 69 1.7% Active
Publication timeline 3,041 dated records
3,041 records since 2020
Annual records Cumulative line
Default publication index

Latest publications

569 records from the full SQLite publication database, sorted by newest first.

Result settings and export data
Updated Jul 5, 2026 01:22 UTC
Checking for newly indexed publications...
Page 2 of 29

Sex-specific increased reactivity of the PVT and prolonged PVT→CeA circuit engagement following psilocin administration

The psychedelic psilocybin has shown therapeutic potential, yet underlying neural mechanisms remain poorly understood. We investigated the impact of psilocin-the active metabolite of psilocybin-on basal activity and reactivity within the paraventricular nucleus of the thalamus (PVT) and PVT projections to central amygdala (CeA) in rats. Psilocin administrati...

Severe Illness Associated with Eating Mushroom-Containing Chocolate Products - United States, January-October 2024.

In late spring 2024, CDC was alerted to an outbreak of poisoning potentially associated with eating Diamond Shruumz microdosing chocolate bars. Diamond Shruumz microdosing chocolate bars are edible products designed so that small doses of mushroom-derived psychoactive compounds and other psychoactive ingredients can be eaten in a presectioned serving. In res...

Psilocin fosters neuroplasticity in iPSC-derived human cortical neurons.

Psilocybin is studied as innovative medication in anxiety, substance abuse and treatment-resistant depression. Animal studies show that psychedelics promote neuronal plasticity by strengthening synaptic responses and protein synthesis. However, the exact molecular and cellular changes induced by psilocybin in the human brain are not known. Here, we treated h...

The QUANTUM Trip Trial - Psilocybin-assisted Therapy for Reducing Alcohol Intake in Patients With Alcohol Use Disorder: A Randomized, Double-blinded, Placebo-controlled Clinical Trial.

Note: The trial is only eligible for citizens of Denmark. The purpose of this project is to assess the treatment efficacy of a single high dose of psilocybin administered within a protocol of psychological support to patients diagnosed with alcohol use disorder (AUD). To establish efficacy, we will investigate a single dose of psilocybin versus placebo in a ...

Psilocybin: Chemical Foundations and Emerging Therapeutic Potential

Psilocybin, chemically known as (4-phosphoryloxy-N, N-dimethyltryptamine, 4-PODMT), is derived from the psychoactive mushroom genus, Psilocybe. Of the four active metabolites, psilocin readily enters systemic circulation. The psychoactive effects of psilocin are thought to arise through partial agonist effects at the 5-HT2A receptor. Psychedelic drugs, inclu...

Pharmacotherapy in Disorders of Consciousness: A Mechanism-Based Review.

Disorders of consciousness pose major therapeutic challenges owing to the complexity of underlying brain dysfunctions. Current pharmacological interventions explored in disorders of consciousness target distinct molecular systems, including dopaminergic modulators (amantadine, levodopa, apomorphine, bromocriptine, selegiline, methylphenidate, and modafinil),...

Unknown journal 2026-03-23 Gillet A, Geron C, Vitello MM, Lejeune N.

Integrated 5-HT2A -TrkB and G protein signaling in serotonergic psychedelic responses

Serotonergic psychedelics have attracted considerable interest as promising therapeutic agents. However, the molecular mechanisms linking their acute hallucinogenic-like effects to longer-lasting neuroplastic responses remain incompletely understood, partly because of the scarcity of native neural models suitable for mechanistic studies. Here, we developed a...

A fungus among us: investigating queensland’s largest magic mushroom growing operation

In April 2024, FSQ Forensic Chemists attended Queensland’s largest mushroom growing operation. Seized items included: 219 50 L plastic tubs of mushrooms in growth medium, bags of dried mushroom material, sterilised grain bags and spores in liquid. In consultation with QPS, six exhibits were selected for illicit drug analysis. Fresh mushrooms were harvested a...

Behavioural investigations of psilocybin in non-human animals 1962-2021: A scoping review

Abstract Background and Aims Psilocybin is a psychedelic compound that may hold promise for a wide range of human health conditions, yet the identification of therapeutic processes and mechanisms of action remains exploratory. We conducted a scoping review of pre-clinical behavioural investigations of psilocybin in non-human animals to identify behavioural e...

Inhibition of cortico-amygdala projections underlies affective bias modification by psilocybin

Psilocybin, a serotonergic psychedelic, can produce rapid and enduring antidepressant effects in patients with major depressive disorder (MDD)[1, 2], yet the neural mechanisms underlying these effects remain unclear. Negative affective biases are an important neuropsychological mechanism central to the development and perpetuation of MDD[3]. Using a translat...

Serotonergic modulation of cortical gamma synchronization: right-lateralized psilocin effects on 40 Hz auditory steady-state responses in rats.

Auditory steady-state responses (ASSRs), particularly at 40 Hz, are promising biomarkers for psychiatric disorders involving dysregulated neural synchronization. Although most ASSR studies have focused on the glutamatergic system, the serotonergic system, specifically 5-HT2A receptor signaling, has received limited attention. Psilocin, the active metabolite ...

Unknown journal 2026-03-03 Griškova-Bulanova I, Vejmola Č, Páleníček T.

Synthesis and Characterization of Psilocybin Metabolites and Deuterated Analogs

To support ongoing clinical trials, the major human metabolites of psilocybin were synthesized on a preparative scale, specifically psilocin-O-glucuronide and 4-hydroxyindole-3-acetic acid (4-HIAA), along with putative minor metabolites and several deuterium-labeled derivatives. Psilocybin, psilocin, psilocin-O-glucuronide, and 4-HIAA were assayed for engage...

Psilocin as a Broad Inhibitor of CYP450 Enzymes: Integrated In Vitro and In Silico Evidence

Background: Psilocybin is a psychoactive compound found in hallucinogenic mushrooms and is rapidly dephosphorylated in vivo to psilocin, its pharmacologically active metabolite. Despite the growing clinical and scientific interest in these substances, information regarding their interaction with cytochrome P450 (CYP450) enzymes remains scarce, raising concer...

The Effects of Psilocybin in Healthy Volunteers: Psychological, Biochemical and Electrophysiological Biomarkers.

In this study, participants will received either psilocybin (the active ingredient found in certain mushrooms) or an inactive placebo (a look-alike tablet with no active drug). The psilocybin is supplied by Filament Health (Burnaby, British Columbia). After psilocybin ingestion, the body quickly converts it into psilocin, which is the form that produces the ...

Psilocin glucuronide in whole blood: a stable and useful biomarker of psilocybin intake

Detecting psilocybin use is challenging because it rapidly converts to its psychoactive metabolite psilocin, and both compounds are unstable in blood. Bufotenin, a structural isomer of psilocin, may exhibit comparable instability in blood. For reliable detection, we developed and validated an LC-MS/MS method to simultaneously quantify psilocin, bufotenin, an...

Acute psilocin increased cortical activity in rat

Psilocin, a naturally occurring hallucinogenic component of magic mushrooms, exerts notable psychoactive effects in both humans and rodents. However, the underlying mechanisms remain not fully understood. Blood-oxygenation level-dependent (BOLD) functional magnetic resonance imaging (fMRI) is a valuable tool in many preclinical and clinical trials for invest...

We Licked the Toads so You Don't Have to: A Comprehensive Analysis of the Chemical Syntheses of the Classical Psychedelics Bufotenin(e) and 5-Methoxy-N,N-Dimethyltryptamine.

Bufotenin (also spelt as bufotenine) and its methylated derivative, 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), are potent psychedelics that are found in many plants but also excreted by some species of toads. The compounds are regulated differently around the world, and although used in traditional medicine, 20-century prohibition culture has slowed resea...

Regarding “The molecular mechanisms through which psilocybin prevents suicide: evidence from network pharmacology and molecular docking analyses”

Clinical investigations into the therapeutic actions of psilocybin have been the focus of much attention in recent years as duly cited in the manuscript.The authors of the present manuscript discuss potential targets through which psilocybin may help prevent suicide using computational network pharmacology coupled with molecular docking investigations.Unfort...

Design, Synthesis, and Pharmacokinetic Profiling of Fluorinated Reversible N -Alkyl Carbamate Derivatives of Psilocin for Sub-Hallucinogenic Brain Exposure

High Resolution Image Download MS PowerPoint Slide Psilocybin, the phosphorylated prodrug of psilocin, holds therapeutic promise across a range of neuropsychiatric conditions, yet its clinical utility is constrained by acute psychoactive effects. Here, we report the rational design, synthesis, and evaluation of a focused library of fluorinated reversible N -...

Live source coverage

4,054 indexed records across 8 active sources.

3,317Published
450Preprints
287Clinical trials
  1. Europe PMC 1,652 records · 40.7%
  2. OpenAlex 1,401 records · 34.6%
  3. ClinicalTrials.gov 287 records · 7.1%
  4. PubMed 278 records · 6.9%
  5. PsyArXiv 191 records · 4.7%
  6. bioRxiv 142 records · 3.5%
  7. Crossref 69 records · 1.7%
  8. medRxiv 34 records · 0.8%

Counts exclude hidden records and curated false positives. Preprints remain labeled as not peer reviewed in search results and exports.